03 Jan 2019 by admin in UncategorizedComments Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda
05 Dec 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 Clinical Trial of CNTX-4975 for the Treatment of Moderate to Severe Knee Osteoarthritis Pain
13 Nov 2018 by admin in UncategorizedComments Tempest Data Provide POC for PPAR Alpha’s Role in Cancer
06 Nov 2018 by admin in UncategorizedComments resTORbio Appoints Michael Grissinger to its Board of Directors
06 Nov 2018 by admin in UncategorizedComments Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018
05 Nov 2018 by admin in UncategorizedComments Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody®
16 Oct 2018 by admin in UncategorizedComments Centrexion Therapeutics Announces Two CNTX-4975 Presentations at the 2018 American College of Rheumatology Annual Meeting
